Laurence Reilly

Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial

T. Brümmendorf, J. Cortes, M. Deininger, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bosutinib (BOS) versus imatinib (IM) for newly diagnosed chronic myeloid leukemia (CML): Initial results from the BFORE trial.

T. Brümmendorf, J. Cortes, M. Deininger, 2017 .

Efficacy and safety of as-needed albuterol/budesonide versus albuterol in adults and children aged ≥4 years with moderate-to-severe asthma: rationale and design of the randomised, double-blind, active-controlled MANDALA study

F. Albers, A. Papi, B. Chipps, 2021, BMJ Open Respiratory Research.

Combined 633-nm and 830-nm led treatment of photoaging skin.

David J Goldberg, D. Goldberg, R. Phelps, 2006, Journal of drugs in dermatology : JDD.

Albuterol/budesonide for the treatment of exercise-induced bronchoconstriction in patients with asthma: the TYREE study.

F. Albers, A. Papi, B. Chipps, 2021, Annals of Allergy, Asthma & Immunology.

Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: 12-Month Patient-Reported Outcomes from the BFORE Trial

T. Brümmendorf, J. Cortes, M. Deininger, 2017 .